antibody enhancing the cancer treatment response was

accepted for publication by Gut Microbes(2023 IF: 12.2).

2.Company name:Microbio Co., LTD.

3.Relationship to the Company (please enter ”head office” or

”subsidiaries”):head office

4.Reciprocal shareholding ratios:NA

5.Cause of occurrence:

(1)Microbio’s Symbiota products: MS-20 is a cutting-edge postbiotic

successfully developed from Microbio’s proprietary symbiotic

anaerobic fermentation technology using multi-strain probiotics.

It is the first approved new drug as an oral adjuvant for cancer

therapy in Taiwan.

(2)The study showed that MS-20 in combination with anti-PD1 antibody

significantly inhibited tumor growth through increasing activated

CD8+ T cells and decreasing suppressive CD8+ T cells in the tumor

microenvironment of animal models. MS-20 also modulated the microbiota

of cancer patients ex vivo and increased the abundance of bacteria

species associated with good immunotherapy responses. The finding was

accepted and published by a SCI journal, Gut Microbes.

6.Countermeasures:None

7.Any other matters that need to be specified(the information

disclosure also meets the requirements of Article 7, subparagraph 9

of the Securities and Exchange Act Enforcement Rules, which brings

forth a significant impact on shareholders rights or the price of

the securities on public companies.):

(1)Symbiota are the gut microbiome based products successfully developed

by Microbio’s proprietary symbiotic anaerobic fermentation technology

using multi-strain probiotics and achieved US GRAS （Generally

Recognized as Safe）conclusion this month, which is equivalent to

obtaining international market sales qualification. The finding on

MS-20, which also belongs to the Symbiota portfolio, in combination with

anti-PD1 therapy was accepted for publication by a renowned

international journal, which has positive benefits on the international

market entry for the products.

(2)Although immunotherapy has been regarded as a promising treatment for

cancer, the response rate was low. Modulation of gut microbiota has been

regarded as a potential strategy to elevate the efficacy of

immunotherapy. MS-20 enhances the gut microbiota-associated antitumor

effects of anti-PD1 antibody and the clinical trial of MS-20 in

combination with anti-PD1 antibody is conducted in Kaohsiung CGMH, TMUH,

SHH, WFH, KMUH, EDAH and Linkou CGMH.

(3)Gut Microbes is a renowned international journal that published top

research articles on Microbiology and is ranked the 8th out of 143

journals in the Gastroenterology and Hepatology category, and is ranked

the 9th out of 161 journals in the Microbiology category.

(4)The article published in Gut Microbes is available to access via link

as https://doi.org/10.1080/19490976.2024.2380061